ClinicalTrials.gg
RecruitingNCT07195695Updated Nov 2, 2026

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

A Phase 3 interventional study of Zongertinib and Pembrolizumab in Non-small Cell Lung Cancer, sponsored by Boehringer Ingelheim. Recruiting at 203 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 2, 2026Site recruiting status changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Boehringer Ingelheim.

Planned enrollment
10th of 49
400 · median 44
Started
2026
with 1 other
Phase 3
14 of 68
1 open now
Registered
67th of 68
by date

Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 10th largest by planned enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 in phase 3, and was the 67th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy.

Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.

Read the detailed description

This is a global, randomized, open-label, Phase 3 study designed to assess the efficacy and safety of zongertinib as adjuvant therapy in participants with completely resected Stage II-IIIB NSCLC and HER2 TKD-activating mutations.

Participants must have undergone complete resection and received perioperative systemic therapy consistent with current standards, including either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy.

After completing surgery and required systemic treatment, eligible participants are randomized 1:1 to receive either Zongertinib taken orally once daily for up to 3 years, or standard treatment, which may include an approved adjuvant immunotherapy agent administered according to its label, or observation, depending on local clinical practice and patient status.

The primary objective is to evaluate whether zongertinib improves disease-free survival (DFS) compared with standard treatment. Secondary objectives include overall survival (OS), safety, tolerability, and patient-reported outcomes.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial
  2. Patients must be ≥18 years old or over the legal age of consent in their country
  3. Male or female patients. Women of (WOCBP) must be ready and able to use dual highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the study protocol
  4. mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor receptor 2 (HER2) mutations
  5. Histology and tumor sample: confirmed diagnosis of primary NSCLC
  6. An sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status
  7. Staging: Pretherapeutic classification not exceeding Stage IIIB
  8. Performance status and organ function:

    • (ECOG) score of 0 or 1
    • Adequate organ function based on laboratory values Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Diagnosis of NSCLC with mixed histology/positive neuroendocrine markers (synaptophysin/CD56)
  2. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization
  3. Treatment with radiation therapy for primary NSCLC
  4. Co-occurring actionable mutation with approved targeted therapy (e.g. Epidermal growth factor receptor (EGFR) or Anaplastic lymphoma kinase (ALK))
  5. Any drug within 5 half-lives of the compound or any of its related material, if known
  6. History or presence of

    • Active or known pre-existing or history of non-infectious interstitial lung disease/pneumonitis
    • Active infectious disease requiring systemic therapy
    • Uncontrolled gastrointestinal disorders affecting drug intake/absorption
    • Previous or concomitant within the last 3 years, except certain effectively treated cancers
    • Significant and/or uncontrolled cardiovascular abnormalities, corrected for heart rate by Fridericia formula (QTcF) >470 msec, or \<50% Further exclusion criteria apply.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Zongertinib treatment arm

    Drug: Zongertinib

  • Active comparator
    Standard of Care (SoC) treatment arm

    Drug: Pembrolizumab · Drug: Atezolizumab · Drug: Durvalumab · Drug: Nivolumab

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-free survival (DFS) by investigator's assessment

    DFS is defined as the time from randomization until recurrence of tumor or death from any cause, whichever occurs earlier

    Time frame: up to 8 years and 5 months

Secondary outcomes

  1. Key secondary endpoint: Overall survival (OS), defined as the time from randomization until death from any cause

    Time frame: up to 8 years and 5 months

  2. Occurrence of trial-related Adverse Events (AEs) ≥ Grade 3 from first treatment administration (or from randomization for patients in the observation arm) until the earliest of tumor recurrence or 3 years since treatment start

    AEs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: up to 3 years

07

Study locations

172 of 203 sites recruiting

Showing the first 100 of 203 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2032, 73 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 73 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Sep 29, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Feb 26, 2032
CompletionEst.
Sep 2, 2036
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed. 5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Sutter Health · Roseville, United StatesNot yet recruiting→Recruiting
  • Princess Alexandra Hospital · Woolloongabba, AustraliaNot yet recruiting→Recruiting
  • ICESP - Instituto do Cancer do Estado de Sao Paulo · São Paulo, BrazilNot yet recruiting→Recruiting
  • Xiangya Hospital, Central South University · Changsha, ChinaNot yet recruiting→Recruiting
  • Ankara Bilkent Sehir Hastanesi · Türkiye, Turkey (Türkiye)Not yet recruiting→Recruiting
Show 3 added (1 Spain, 1 United States, 1 United Kingdom)
  • Hospital Universitario de Navarra · Pamplona, Spain
  • Texas Oncology - Amarillo · Amarillo, United States
  • The Christie · Manchester, United Kingdom
Show 2 removed
  • Complejo Hospitalario de Navarra · Pamplona, Spain
  • The Christie Hospital · Manchester, United Kingdom
across 3 updates, Oct 7, 2026 – Nov 2, 2026
Show all 3 updates
  1. Nov 2, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 United Kingdom)
    • Texas Oncology - Amarillo · Amarillo, United States
    • The Christie · Manchester, United Kingdom
    Show 1 removed
    • The Christie Hospital · Manchester, United Kingdom
  2. Oct 15, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Xiangya Hospital, Central South University · Changsha, ChinaNot yet recruiting→Recruiting
    • Ankara Bilkent Sehir Hastanesi · Türkiye, Turkey (Türkiye)Not yet recruiting→Recruiting
  3. Oct 7, 2026
    1 site added, 1 site removed. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Sutter Health · Roseville, United StatesNot yet recruiting→Recruiting
    • Princess Alexandra Hospital · Woolloongabba, AustraliaNot yet recruiting→Recruiting
    • ICESP - Instituto do Cancer do Estado de Sao Paulo · São Paulo, BrazilNot yet recruiting→Recruiting
    Show site
    • Hospital Universitario de Navarra · Pamplona, Spain
    Show 1 removed
    • Complejo Hospitalario de Navarra · Pamplona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07195695
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Jan 16, 2026
Primary completion
Feb 26, 2032 (estimated)
Completion
Sep 2, 2036 (estimated)
Last update
Nov 2, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zongertinib

Start the discussion